Use of corticotropin releasing factor antagonists and related compositions
AssigneePfizer Inc.
InventorsErnest S. Hamanaka, Yuhpyng Liang Chen
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.
Claims30
A method of treating or preventing Syndrome X in an animal which comprises administering to said animal an amount of a corticotropin releasing factor antagonist.
A pharmaceutical composition for treating or preventing Syndrome X which comprises an amount of a corticotropin releasing factor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent.
A kit which comprises an amount of a corticotropin releasing factor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent in a first unit dosage form;
- an amount of a glucocorticoid receptor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent in a second unit dosage form;
- and a container for containing said first and second dosage forms;
- wherein the amount of the corticotropin releasing factor antagonist and the amount of the glucocorticoid receptor antagonist result in a therapeutic effect.
Dependencies are inferred from the claim text.